Private Investors

Offering deal and non-deal services to our private investors as they look for opportunities in the Precision Medicine market

 

The incredible pace of innovation across the Precision Medicine ecosystem offers huge opportunities for investors, but they need advisors who can help them seamlessly navigate the complexities associated with this rapidly evolving field of healthcare. We understand the regulatory, commercial, and operational complexities unique to the Precision Medicine industry and provide a client-centric, integrated suite of services across the deal lifecycle to assist our clients in achieving business results. The ability to go beyond standard diligence methods will be increasingly important in the post-COVID-19 M&A market, and our multidisciplinary approach provides clients with critical insights into value opportunities and obstacles to value, at deal speed, underpinned by our proprietary set of tools and methodologies.


Team & Contacts

Kristin C. Pothier

Kristin C. Pothier

Global & National, HCLS Deal Advisory & Strategy Leader, KPMG US

+1 617 549 2779
Alasdair Milton, PhD

Alasdair Milton, PhD

Managing Director, Healthcare and Life Sciences Strategy, KPMG US

+1 617-988-5419
Varun Renjen, MD

Varun Renjen, MD

Managing Director, Life Sciences Deal Advisory and Strategy, KPMG US

+1 973-467-9650
Puja Ghelani

Puja Ghelani

Director, Healthcare and Life Sciences Strategy, KPMG US

+1 918-845-2389